Lankide:Bcpgials/Proba orria
subset[aldatu | aldatu iturburu kodea]
Title | Page ID | Namespace | Size (bytes) | Last change |
---|---|---|---|---|
Blood–brain barrier | 84936 | 0 | 54393 | 20190117105105 |
Intravenous therapy | 178769 | 0 | 40184 | 20190108160032 |
Route of administration | 334816 | 0 | 29025 | 20190115070859 |
Subcutaneous injection | 334820 | 0 | 4046 | 20190107095300 |
Intramuscular injection | 334821 | 0 | 8579 | 20190107095300 |
Therapeutic index | 334955 | 0 | 20399 | 20181231145536 |
Injection | 665909 | 0 | 14929 | 20190111154901 |
Cytochrome P450 | 709137 | 0 | 49994 | 20190117100127 |
Therapeutic drug monitoring | 739219 | 0 | 4914 | 20181217063807 |
Bioavailability | 769021 | 0 | 22147 | 20181204133035 |
ADME | 826690 | 0 | 6152 | 20181208191145 |
Bioequivalence | 998103 | 0 | 14201 | 20181202155139 |
Prodrug | 1017427 | 0 | 12119 | 20190105155457 |
Cimetidine | 1018112 | 0 | 50117 | 20190107221409 |
CYP3A4 | 1024582 | 0 | 48387 | 20190117100132 |
CYP2D6 | 1024815 | 0 | 29535 | 20190117100132 |
CYP2E1 | 1024830 | 0 | 23203 | 20190117100132 |
Polypharmacy | 1099391 | 0 | 25926 | 20190103145504 |
Drug interaction | 1099396 | 0 | 44028 | 20190115190456 |
Toxicokinetics | 1112289 | 0 | 3616 | 20181124175936 |
Drug metabolism | 1173475 | 0 | 28070 | 20190117062839 |
Toxication | 1173482 | 0 | 8800 | 20181117220121 |
First pass effect | 1173539 | 0 | 4796 | 20181231150249 |
Volume of distribution | 1272743 | 0 | 7013 | 20181109232927 |
Aromatase | 1415048 | 0 | 27049 | 20190117100137 |
Physiologically based pharmacokinetic modelling | 1566437 | 0 | 25277 | 20181117220123 |
Effective half-life | 1728145 | 0 | 2594 | 20181010124401 |
Drug action | 2070741 | 0 | 5915 | 20181221103905 |
Polymersome | 2218269 | 0 | 6943 | 20180929133937 |
Clearance | 2402393 | 0 | 13244 | 20190114112233 |
Haber's rule | 2463278 | 0 | 3182 | 20181004165113 |
CYP2A6 | 2516515 | 0 | 11644 | 20190117100155 |
Enteric coating | 2910903 | 0 | 9850 | 20190113221504 |
Trough level | 2962530 | 0 | 1936 | 20181010124518 |
Biological half-life | 3206099 | 0 | 13872 | 20181117220129 |
Loading dose | 3291372 | 0 | 3766 | 20181109232927 |
Distribution | 3665681 | 0 | 9706 | 20181127032709 |
Microdosing | 3845621 | 0 | 5774 | 20190114190444 |
Ethnopsychopharmacology | 4189719 | 0 | 7015 | 20181014221721 |
P450-containing systems | 4277840 | 0 | 10609 | 20190117100221 |
CYP1A2 | 4320289 | 0 | 22911 | 20190117100221 |
Epoxyeicosatrienoic acid | 4367754 | 0 | 49168 | 20190115133053 |
Grapefruit–drug interactions | 4387617 | 0 | 55511 | 20181231234649 |
Initial volume of distribution | 4629153 | 0 | 1687 | 20181221105004 |
CYP2C9 | 4779665 | 0 | 27521 | 20190117100228 |
CYP2C19 | 4779761 | 0 | 23851 | 20190117100228 |
CYP2C8 | 4779795 | 0 | 13153 | 20190117100228 |
Cytochrome P450 | 5119921 | 0 | 14296 | 20190117100234 |
Enzyme induction and inhibition | 5245810 | 0 | 2570 | 20180929134736 |
Context-sensitive half-life | 5507641 | 0 | 5320 | 20181222034944 |
CYP1B1 | 5900320 | 0 | 8431 | 20190117100250 |
CYP17A1 | 5914077 | 0 | 19201 | 20190117100250 |
Plasma protein binding | 6025636 | 0 | 8443 | 20190114190623 |
Binding potential | 6075099 | 0 | 5734 | 20180929134930 |
Absorption | 6194872 | 0 | 8109 | 20181227105718 |
Targeted drug delivery | 6470547 | 0 | 29101 | 20181117220136 |
CYP27A1 | 6700732 | 0 | 10770 | 20190117100419 |
Cholesterol side-chain cleavage enzyme | 6796314 | 0 | 22369 | 20190117100422 |
Dosage form | 7481381 | 0 | 5887 | 20190112170427 |
Osmotic-controlled release oral delivery system | 8031252 | 0 | 12541 | 20190107095300 |
21-Hydroxylase | 8852888 | 0 | 17070 | 20190117100519 |
Modified-release dosage | 9360334 | 0 | 24525 | 20190115023910 |
NONMEM | 9365585 | 0 | 2303 | 20181023170705 |
Pharmacokinetics | 9674107 | 0 | 39961 | 20190111155232 |
Cytochrome P450 reductase | 9736045 | 0 | 18592 | 20190117100553 |
Pharmacometrics | 10162690 | 0 | 5168 | 20190108081442 |
Dose | 10449471 | 0 | 19391 | 20181117220144 |
CYP2B6 | 10456228 | 0 | 15614 | 20190117100638 |
CYP3A7 | 10680502 | 0 | 2223 | 20190117100650 |
Lanosterol 14 alpha-demethylase | 10906045 | 0 | 15122 | 20190117100705 |
PEGylation | 10931846 | 0 | 17579 | 20181125212916 |
Bolus | 12238660 | 0 | 4028 | 20190107095300 |
Dissolution testing | 12458572 | 0 | 9824 | 20180727142641 |
Flip-flop kinetics | 13589014 | 0 | 1806 | 20170925222345 |
Dose dumping | 14007566 | 0 | 1873 | 20190105155735 |
Cholesterol 24-hydroxylase | 14045189 | 0 | 18819 | 20190117100815 |
IdMOC | 14350461 | 0 | 3830 | 20190116030740 |
Ion trapping | 14440094 | 0 | 4782 | 20181030184709 |
Active metabolite | 14564960 | 0 | 3539 | 20190116030743 |
CYP3A | 14798557 | 0 | 8481 | 20190117100835 |
Table of volume of distribution for drugs | 14848284 | 0 | 1952 | 20180929140604 |
Compartment | 14848805 | 0 | 1715 | 20181109232927 |
Table of medication secernated in kidney | 14848938 | 0 | 4653 | 20181026163436 |
Skin popping | 15151817 | 0 | 2523 | 20190107135449 |
Magnetic marker monitoring | 15342613 | 0 | 2193 | 20181010125624 |
Simcyp Simulator | 16157480 | 0 | 3740 | 20180929140750 |
Maintenance dose | 16698745 | 0 | 2530 | 20181109232927 |
Free fraction | 16823207 | 0 | 3223 | 20181221113956 |
CYP2C9*13 | 18420839 | 0 | 7711 | 20190117101022 |
Rate of infusion | 18872320 | 0 | 1105 | 20181109232927 |
Elimination rate constant | 19094964 | 0 | 3366 | 20181109232927 |
Dermal patch | 20016657 | 0 | 1211 | 20190116030827 |
CYP2C9*3 | 22685256 | 0 | 1478 | 20190117101216 |
Chemotactic drug-targeting | 22787622 | 0 | 1696 | 20181221115703 |
Cmin | 22982241 | 0 | 1264 | 20181222035059 |
Cmax | 23184916 | 0 | 3490 | 20190114174555 |
Area under the curve | 23518221 | 0 | 3802 | 20181109005510 |
Bioanalysis | 23604382 | 0 | 6026 | 20180929142056 |
Dihydromethysticin | 24225451 | 0 | 4389 | 20181223230630 |
Plateau principle | 24608545 | 0 | 22889 | 20180522075742 |
Epsilon-Viniferin | 24650277 | 0 | 7034 | 20181215042312 |
Onset of action | 24697544 | 0 | 1906 | 20181222035104 |
Intradermal injection | 25284347 | 0 | 3397 | 20181024105058 |
Proadifen | 25296374 | 0 | 3252 | 20181214171239 |
Amentoflavone | 26370272 | 0 | 6224 | 20190110031351 |
PK/PD models | 26390451 | 0 | 5349 | 20181124062011 |
Oculomucocutaneous syndrome | 28104937 | 0 | 1640 | 20190106161817 |
Lipophilic efficiency | 28819446 | 0 | 5742 | 20181119052101 |
Parallel artificial membrane permeability assay | 28893371 | 0 | 5083 | 20181117220204 |
Cobicistat | 29240014 | 0 | 10662 | 20190111100418 |
Cooperstown cocktail | 31190054 | 0 | 2748 | 20181221121832 |
PottersWheel | 31376465 | 0 | 8275 | 20190115122951 |
Rhapontigenin | 35281330 | 0 | 3510 | 20181214171240 |
Blood–gas partition coefficient | 35737600 | 0 | 4185 | 20181205223518 |
Liberation | 39490884 | 0 | 4011 | 20181222035144 |
Elimination | 39490943 | 0 | 7081 | 20190116031029 |
20-Hydroxyeicosatetraenoic acid | 47836404 | 0 | 79670 | 20190115133053 |
Epoxydocosapentaenoic acid | 49599350 | 0 | 15811 | 20181016222046 |
Epoxyeicosatetraenoic acid | 49854427 | 0 | 23013 | 20180929145841 |
Cytochrome P450 omega hydroxylase | 50110441 | 0 | 12100 | 20180929145902 |
Residence time | 50390340 | 0 | 32156 | 20190110022349 |
Variable volume pharmacokinetic models | 51553756 | 0 | 4901 | 20180929150119 |
Intracerebroventricular injection | 53597220 | 0 | 2784 | 20181117220233 |
Physical pharmacy | 57989671 | 0 | 2480 | 20190108191157 |
Drug accumulation ratio | 57998655 | 0 | 315 | 20181010132647 |
Cmean | 58105226 | 0 | 584 | 20181010132652 |